Skip to main content

A discussion by Safir Anand on the laws and codes of practices governing advertising of medicinal products in India.

In India, pharmaceutical advertising is governed by The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and The Drugs and Cosmetics Rules, 1945. However these Acts do not lay down the minimum essential information requirements for advertisements. The Organization of Pharmaceutical Producers of India in its Code of Pharmaceutical Marketing Practices also provide guidelines for the information requirements in advertisements and the allowed practices for the promotion of pharmaceutical products. The Indian department of Pharmaceuticals has also come up with a Code of Marketing Practice for Indian Pharmaceutical Industry which is a voluntary code of Marketing Practices for Indian Pharmaceutical Industry.

This chapter was published in ICLG’s Pharmaceutical Advertising 2013.

To continue reading, please contact us at email@anandandanand.com

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Jan 15, 2026

First published by Lexology. Authors: Safir Anand, Mudit Kaushik and Sehr Anand The handling of price sensitive corporate information has become increasingly

The Regulatory Cost of Informal Digital Disclosures
News & Updates
Jan 02, 2026

First published by Lexology. Authors: Pravin Anand, Saif Khan, Shobhit Agarwal and Prajjwal Kushwaha A. Background B. Legal Issues Addressed C. Directions

Landmark Ruling On Domain Name Fraud and Systematic Reforms in Digital Commerce
Thought Leadership
Jan 01, 2026

First published on Enterprise IT World. Authored by Subroto Kumar Panda As we stand on the final day of 2025, reflecting on a year of dizzying

The Great Dissolve: Re-Engineering Enterprise Workflows for the 2026 AI Paradigm
Thought Leadership
Dec 19, 2025

First published on Express Computer. Authored by Subroto Kumar Panda The notification of the Digital Personal Data Protection (DPDP) Rules, 2025, marks

The DPDP: An 18-month compliance imperative for the C-suite